Clinical data
ATC code none
CAS Number 185428-18-6
PubChem (CID) 3055168
ChemSpider 2316729
UNII 3A3N0634Q6 YesY
Chemical and physical data
Formula C20H19N3O4S
Molar mass 397.448 g/mol
3D model (Jmol) Interactive image

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]

It is being developed by Daiichi Sankyo.


  1. Schimke K; Davis ™ (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.
  2. Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC (2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes Obes Metab. 13 (9): 806–13. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364.

This article is issued from Wikipedia - version of the 6/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.